Predictive factors for response to Lamivudine in chronic hepatitis B
BACKGROUND: Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment. AIM: To investigate predictive factors of response, using a quantitative method with high sensitivity. METHODS: We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence...
Main Authors: | , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Universidade de São Paulo (USP)
2000
|
Subjects: | |
Online Access: | https://doaj.org/article/d2d07862ef4f457cbb472cffa1c40960 |
id |
ftdoajarticles:oai:doaj.org/article:d2d07862ef4f457cbb472cffa1c40960 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:d2d07862ef4f457cbb472cffa1c40960 2024-09-09T19:26:13+00:00 Predictive factors for response to Lamivudine in chronic hepatitis B Luiz Caetano da SILVA Luís Edmundo Pinto da FONSECA Flair José CARRILHO Venâncio Avancini Ferreira ALVES Roberta SITNIK João Renato Rebello PINHO 2000-08-01T00:00:00Z https://doaj.org/article/d2d07862ef4f457cbb472cffa1c40960 EN eng Universidade de São Paulo (USP) http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652000000400003&tlng=en https://doaj.org/toc/1678-9946 1678-9946 https://doaj.org/article/d2d07862ef4f457cbb472cffa1c40960 Revista do Instituto de Medicina Tropical de São Paulo, Vol 42, Iss 4, Pp 189-196 (2000) Hepatitis B HBV Lamivudine HBV-DNA PCR bDNA Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2000 ftdoajarticles 2024-08-05T17:49:30Z BACKGROUND: Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment. AIM: To investigate predictive factors of response, using a quantitative method with high sensitivity. METHODS: We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence for viral replication, regardless to their HBeAg status. Lamivudine was given for 12 months at 300 mg daily and 150 mg thereafter. Response was considered when DNA was undetectable by PCR after 6 months of treatment. Viral replication was monitored by end-point dilution PCR. Mutation associated with resistance to lamivudine was detected by DNA sequencing in non-responder patients. RESULTS: Response was observed in 23/35 patients (65.7%) but only in 5/15 (33.3%) HBeAg positive patients. Only three pre-treatment variables were associated to low response: HBeAg (p = 0.006), high viral load (DNA-VHB > 3 x 10(6) copies/ml) (p = 0.004) and liver HBcAg (p = 0.0028). YMDD mutations were detected in 7/11 non-responder patients. CONCLUSIONS: HBeAg positive patients with high viral load show a high risk for developing drug resistance. On the other hand, HBeAg negative patients show a good response to lamivudine even with high viremia. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Hepatitis B HBV Lamivudine HBV-DNA PCR bDNA Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
spellingShingle |
Hepatitis B HBV Lamivudine HBV-DNA PCR bDNA Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Luiz Caetano da SILVA Luís Edmundo Pinto da FONSECA Flair José CARRILHO Venâncio Avancini Ferreira ALVES Roberta SITNIK João Renato Rebello PINHO Predictive factors for response to Lamivudine in chronic hepatitis B |
topic_facet |
Hepatitis B HBV Lamivudine HBV-DNA PCR bDNA Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
description |
BACKGROUND: Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment. AIM: To investigate predictive factors of response, using a quantitative method with high sensitivity. METHODS: We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence for viral replication, regardless to their HBeAg status. Lamivudine was given for 12 months at 300 mg daily and 150 mg thereafter. Response was considered when DNA was undetectable by PCR after 6 months of treatment. Viral replication was monitored by end-point dilution PCR. Mutation associated with resistance to lamivudine was detected by DNA sequencing in non-responder patients. RESULTS: Response was observed in 23/35 patients (65.7%) but only in 5/15 (33.3%) HBeAg positive patients. Only three pre-treatment variables were associated to low response: HBeAg (p = 0.006), high viral load (DNA-VHB > 3 x 10(6) copies/ml) (p = 0.004) and liver HBcAg (p = 0.0028). YMDD mutations were detected in 7/11 non-responder patients. CONCLUSIONS: HBeAg positive patients with high viral load show a high risk for developing drug resistance. On the other hand, HBeAg negative patients show a good response to lamivudine even with high viremia. |
format |
Article in Journal/Newspaper |
author |
Luiz Caetano da SILVA Luís Edmundo Pinto da FONSECA Flair José CARRILHO Venâncio Avancini Ferreira ALVES Roberta SITNIK João Renato Rebello PINHO |
author_facet |
Luiz Caetano da SILVA Luís Edmundo Pinto da FONSECA Flair José CARRILHO Venâncio Avancini Ferreira ALVES Roberta SITNIK João Renato Rebello PINHO |
author_sort |
Luiz Caetano da SILVA |
title |
Predictive factors for response to Lamivudine in chronic hepatitis B |
title_short |
Predictive factors for response to Lamivudine in chronic hepatitis B |
title_full |
Predictive factors for response to Lamivudine in chronic hepatitis B |
title_fullStr |
Predictive factors for response to Lamivudine in chronic hepatitis B |
title_full_unstemmed |
Predictive factors for response to Lamivudine in chronic hepatitis B |
title_sort |
predictive factors for response to lamivudine in chronic hepatitis b |
publisher |
Universidade de São Paulo (USP) |
publishDate |
2000 |
url |
https://doaj.org/article/d2d07862ef4f457cbb472cffa1c40960 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Revista do Instituto de Medicina Tropical de São Paulo, Vol 42, Iss 4, Pp 189-196 (2000) |
op_relation |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652000000400003&tlng=en https://doaj.org/toc/1678-9946 1678-9946 https://doaj.org/article/d2d07862ef4f457cbb472cffa1c40960 |
_version_ |
1809895876440621056 |